Literature DB >> 21998229

Second-generation antidepressants.

G Michael Allan1, Adil S Virani, Noah Ivers.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21998229      PMCID： PMC3192078     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  13 in total

Review 1.  Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications.

Authors:  Hans Melander; Jane Ahlqvist-Rastad; Gertie Meijer; Björn Beermann
Journal:  BMJ       Date:  2003-05-31

Review 2.  Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.

Authors:  Richard A Hansen; Gerald Gartlehner; Kathleen N Lohr; Bradley N Gaynes; Timothy S Carey
Journal:  Ann Intern Med       Date:  2005-09-20       Impact factor: 25.391

3.  Concordance between PHQ-9 scores and patients' experiences of depression: a mixed methods study.

Authors:  Alice Malpass; Alison Shaw; David Kessler; Deborah Sharp
Journal:  Br J Gen Pract       Date:  2010-06       Impact factor: 5.386

Review 4.  Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.

Authors:  David Smith; Carrie Dempster; Julie Glanville; Nick Freemantle; Ian Anderson
Journal:  Br J Psychiatry       Date:  2002-05       Impact factor: 9.319

5.  Monitoring depression treatment outcomes with the patient health questionnaire-9.

Authors:  Bernd Löwe; Jürgen Unützer; Christopher M Callahan; Anthony J Perkins; Kurt Kroenke
Journal:  Med Care       Date:  2004-12       Impact factor: 2.983

Review 6.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.

Authors:  Andrea Cipriani; Toshiaki A Furukawa; Georgia Salanti; John R Geddes; Julian Pt Higgins; Rachel Churchill; Norio Watanabe; Atsuo Nakagawa; Ichiro M Omori; Hugh McGuire; Michele Tansella; Corrado Barbui
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321

Review 7.  Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

Authors:  George I Papakostas; Maurizio Fava
Journal:  Eur Neuropsychopharmacol       Date:  2008-09-26       Impact factor: 4.600

8.  Escitalopram in the treatment of major depressive disorder: a meta-analysis.

Authors:  Sidney H Kennedy; Henning F Andersen; Michael E Thase
Journal:  Curr Med Res Opin       Date:  2009-01       Impact factor: 2.580

9.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

10.  Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Jonathan W Stewart; Andrew A Nierenberg; Michael E Thase; Louise Ritz; Melanie M Biggs; Diane Warden; James F Luther; Kathy Shores-Wilson; George Niederehe; Maurizio Fava
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245
View more
  1 in total

1.  Trends in fall-related mortality and fall risk increasing drugs among older individuals in the United States,1999-2017.

Authors:  Amy L Shaver; Collin M Clark; Mary Hejna; Steven Feuerstein; Robert G Wahler; David M Jacobs
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-02-16       Impact factor: 2.732
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.